N James

..In other disease sites, synchronous chemoradiotherapy has been associated with increased local control and improved survival, as compared with radiotherapy alone...

..The MAMS design will potentially facilitate evaluation and testing of new therapies in this and other diseases...

....

..The endothelin-A receptor (ETAR) has been implicated in the progression of prostate cancer...

..Future studies investigating the timing of chemotherapy, combinations with existing treatments or other novel therapies are underway...

..To examine cancer patients' and carers' use of, and attitudes to, the Internet as an information source compared with other media...

..To determine whether primary care trusts' agreement or refusal to fund sorafenib or sunitinib affects outcomes for patients with metastatic renal cell carcinoma...

..This study showed in both univariate and multivariate analysis that survival is significantly inferior in patients with tumour expressing CA IX. Prospective studies are underway to investigate this correlation in clinical trial setting...

..To re-audit national radiotherapy practice in head and neck cancer to assess the effect of new guidelines...

..These data may be relevant as a diagnostic tool; in providing insight into progression of cancer from normal epithelium; and in identifying novel therapeutic strategies for prostate cancer...

..The overall median survival was 16 months (range 10.1-26.6 months). G plus C every 3 weeks is active and well tolerated in an outpatient setting, even in patients receiving prior platinum-based regimens and with poor renal reserve...

..A national phase III trial BC2001 (www.bc2001.org.uk) exploring the effects of synchronous chemoradiotherapy with this regimen is currently recruiting...

....

..To undertake a national audit of radiotherapy practice in head and neck cancer to estimate compliance with published guidelines and national standards...

..This study shows that over-expression of BCL2 in patients receiving synchronous chemoradiotherapy is an independent indicator of poor survival in muscle invasive TCC of the bladder...

..It also raises the possibility of the future development of CD40/CD40 ligand-based immunotherapy for bladder cancer...

..Our results also raise the possibility of the future development of CD40- and CD40 ligand-based immunotherapy for bladder cancer. This study links proapoptotic and antiapoptotic markers to overall survival...

..Although significant hurdles remain to be overcome, early clinical trial results are encouraging, suggesting that gene therapy may become an important treatment option for prostate cancer...

..The mechanism of this improved response is however likely to be non-immune based as it lacks a memory effect...

..We aim to describe our experience with palliative radiotherapy in this context, relating Biological Effective Dose to outcome...

..To establish the long-term outcome for muscle-invasive transitional cell carcinoma of the bladder treated by radiotherapy with or without neoadjuvant cisplatin...

..In particular we note that the peak (10)B concentration in blood was 28.1 mg/ml for a total BPA administration of 350 mg/kg which is very consistent with the previous experience with BPA-fructose reported by the Helsinki group...

..The PSA relative velocity on therapy decreased in 15/18 (83%) assessable patients compared to pre-study. GM-CSF and MDX-H210 is active in hormone refractory prostate carcinoma with acceptable toxicity; further studies are warranted...

..Overall 12-month survival was 65%. CONCLUSION: Chemoradiotherapy with the five-day schedule is feasible with acceptable toxicity in poor prognosis patients. A randomised trial is being launched...

..To document UK practice in radiotherapy fractionation...